Xencor, Inc Deferred Income Tax Expense (Benefit)
Xencor, Inc (XNCR) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-25
- Xencor, Inc deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- Xencor, Inc deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Xencor, Inc deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Xencor, Inc deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2021-12-31 | $0.00 10-K/A · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |